92 Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-COMET. (October 2019) - Qu, Melody; Chen, Yujie; Zaric, Gregory; Senan, Suresh; Olson, Robert; Harrow, Stephen; John-Baptiste, Ava; Gaede, Stewart; Mulroy, Liam; Schellenberg, Devin; Senthi, Sashendra; Swaminath, Anand; et al.